uniQure (NASDAQ:QURE) Receives Consensus Recommendation of “Buy” from Analysts

Shares of uniQure (NASDAQ:QURE) have earned a consensus rating of “Buy” from the ten brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $33.88.

QURE has been the subject of a number of recent research reports. The Goldman Sachs Group upped their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $20.00 to $52.00 in a research note on Tuesday, December 10th. Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, Mizuho upped their price objective on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday.

uniQure Trading Up 9.8 %

Shares of QURE stock opened at $16.98 on Friday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 1 year low of $3.73 and a 1 year high of $17.71. The firm’s fifty day simple moving average is $8.13 and its 200 day simple moving average is $6.77. The firm has a market capitalization of $827.66 million, a P/E ratio of -3.42 and a beta of 0.89.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The company had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. As a group, sell-side analysts predict that uniQure will post -3.82 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently added to or reduced their stakes in QURE. RTW Investments LP bought a new stake in uniQure during the 3rd quarter worth about $49,000. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new position in uniQure in the third quarter valued at approximately $53,000. Quarry LP bought a new position in uniQure in the third quarter valued at approximately $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the period. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.